Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC

INTRODUCTION: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramer, Vasko, Fernández, René, Lehnert, Wencke, Jiménez-Franco, Luis David, Soza-Ried, Cristian, Eppard, Elisabeth, Ceballos, Matias, Meckel, Marian, Benešová, Martina, Umbricht, Christoph A., Kluge, Andreas, Schibli, Roger, Zhernosekov, Konstantin, Amaral, Horacio, Müller, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036212/
https://www.ncbi.nlm.nih.gov/pubmed/32949253
http://dx.doi.org/10.1007/s00259-020-05022-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036212/
https://www.ncbi.nlm.nih.gov/pubmed/32949253
http://dx.doi.org/10.1007/s00259-020-05022-3

Ejemplares similares